These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
108 related items for PubMed ID: 2059216
1. Preliminary characterization and partial purification of rat uterine nuclear type II Binding sites. Markaverich BM, Gregory RR. Biochem Biophys Res Commun; 1991 Jun 28; 177(3):1283-90. PubMed ID: 2059216 [Abstract] [Full Text] [Related]
2. Purification and characterization of nuclear type II [(3)H]estradiol binding sites from the rat uterus: covalent labeling with [(3)H]luteolin. Markaverich BM, Shoulars K, Brown MA. Steroids; 2001 Sep 28; 66(9):707-19. PubMed ID: 11546559 [Abstract] [Full Text] [Related]
3. Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei. Markaverich BM, Roberts RR, Finney RW, Clark JH. J Biol Chem; 1983 Oct 10; 258(19):11663-71. PubMed ID: 6619136 [Abstract] [Full Text] [Related]
4. Preliminary assessment of luteolin as an affinity ligand for type II estrogen--binding sites in rat uterine nuclear extracts. Markaverich BM, Gregory RR. Steroids; 1993 Jun 10; 58(6):268-74. PubMed ID: 8212072 [Abstract] [Full Text] [Related]
5. An endogenous ligand for type II binding sites in normal and neoplastic tissues. Clark JH, Markaverich BM. Adv Exp Med Biol; 1986 Jun 10; 196():305-15. PubMed ID: 3716924 [Abstract] [Full Text] [Related]
6. Characterization of uterine estrogen receptors by size-exclusion and ion-exchange high-performance liquid chromatography. Madhok TC, Leung BS. Biochem Biophys Res Commun; 1983 Sep 30; 115(3):988-94. PubMed ID: 6626235 [Abstract] [Full Text] [Related]
7. Estradiol receptor of calf uterus: interactions with heparin-agarose and purification. Molinari AM, Medici N, Moncharmont B, Puca GA. Proc Natl Acad Sci U S A; 1977 Nov 30; 74(11):4886-90. PubMed ID: 270721 [Abstract] [Full Text] [Related]
8. Protein purification using a soluble affinity matrix: purification of estrogen receptor with estradiol-polylysine conjugate. Bhattacharjee M, Ali E. Anal Biochem; 1992 Mar 30; 201(2):233-6. PubMed ID: 1632510 [Abstract] [Full Text] [Related]
9. Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen. Attardi B, Happe HK. Endocrinology; 1986 Aug 30; 119(2):904-15. PubMed ID: 3732150 [Abstract] [Full Text] [Related]
12. Estrogen dependent induction of low affinity binding sites in the nuclear fraction of rat uterus. De Hertogh R, Ekka E, Vanderheyden I. J Steroid Biochem; 1986 Jun 30; 24(6):1171-7. PubMed ID: 3736044 [Abstract] [Full Text] [Related]
13. The nuclear estrogen receptor R-II of the goat uterus: distinct possibility that the R-II is the deglycosylated form of the nonactivated estrogen receptor (naER). Karthikeyan N, Thampan RV. Arch Biochem Biophys; 1995 Aug 20; 321(2):442-52. PubMed ID: 7544097 [Abstract] [Full Text] [Related]
14. Eosinophils as the source of uterine nuclear type II estrogen binding sites. Lyttle CR, Medlock KL, Sheehan DM. J Biol Chem; 1984 Mar 10; 259(5):2697-700. PubMed ID: 6698988 [Abstract] [Full Text] [Related]
15. Uterine type II estrogen-binding sites are not of eosinophil origin. Markaverich BM, Roberts RR, Alejandro MA, Clark JH. J Biol Chem; 1986 Jan 05; 261(1):142-6. PubMed ID: 3941067 [Abstract] [Full Text] [Related]
16. Analysis of binding of [3H]Estradiol to the cytosol fraction of rat pancreas: comparison with sites in the cytosol of uterus. Boctor AM, Band P, Grossman A. Endocrinology; 1983 Aug 05; 113(2):453-62. PubMed ID: 6872936 [Abstract] [Full Text] [Related]
17. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. Markaverich BM, Roberts RR, Alejandro MA, Johnson GA, Middleditch BS, Clark JH. J Steroid Biochem; 1988 Aug 05; 30(1-6):71-8. PubMed ID: 3386279 [Abstract] [Full Text] [Related]
18. The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites. Markaverich BM, Roberts RR, Alejandro M, Clark JH. Endocrinology; 1984 Mar 05; 114(3):814-20. PubMed ID: 6697964 [Abstract] [Full Text] [Related]